NewGenIvf Group Limited (NIVF) 株式分析

企業概要

NewGenIvf Group Limited operates as an investment holding company specializing in assisted reproductive services designed to assist couples and individuals with fertility treatments across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The firm functions within the Healthcare sector, specifically categorized under the Medical Care Facilities industry, which denotes its focus on providing specialized clinical interventions rather than manufacturing pharmaceuticals or medical devices. This entity reports a market capitalization of $1.21M and generates annual revenue of $4.73M, while the specific count of employees is not disclosed in the available data. These valuation and revenue figures indicate that the company operates on a very small scale relative to major industry peers, suggesting a niche market position rather than broad market dominance. The minimal market capitalization combined with the limited revenue base reflects a micro-cap status where financial performance is highly sensitive to operational fluctuations in its specific geographic regions of operation.

財務健全性

The company reports a trailing twelve-month revenue of $4.73M alongside a net income of $9.88M, creating a significant discrepancy where net income exceeds gross revenue, which reveals an unusual accounting structure or potential adjustments in the reported figures that distort standard cost-of-sales analysis. The firm's EBITDA stands at $-10,538,352, indicating that despite the reported net income, the underlying operational earnings before interest, taxes, depreciation, and amortization are currently negative. Free cash flow is reported at $-11,179,275, which signifies that the company is consuming cash reserves rather than generating liquidity from its core operations, thereby limiting its immediate financial flexibility for expansion without external financing. Margin analysis reveals a gross margin of 20.2%, suggesting that the cost of goods sold consumes the majority of revenue, while the operating margin of -349.1% highlights severe operational inefficiencies or significant one-time costs impacting the bottom line before interest. Conversely, the profit margin is listed at 209.0%, a figure that implies the net income is derived from sources other than direct operational profitability, such as non-operating income or accounting adjustments. In terms of leverage, the company holds $1.30M in cash against $4.87M in debt, resulting in a debt-to-equity ratio of 18.74, which suggests a highly leveraged balance sheet where liabilities significantly outweigh equity. However, the current ratio of 3.12 indicates that the company possesses sufficient current assets to cover its short-term liabilities more than three times over, pointing to a theoretically comfortable short-term liquidity position despite the high leverage. Return on Equity is reported at 79.4%, while Return on Assets is -36.9%, revealing a divergence where the company appears to generate high returns on shareholder equity but simultaneously fails to generate positive returns on the total asset base employed.

バリュエーション評価

The valuation metrics present a complex picture with a trailing P/E ratio of 0.06 and a forward P/E of 0.23, where the forward multiple is substantially higher than the trailing multiple, implying that the market expects a significant change in earnings structure or a correction in the current earnings figure to justify the stock price in the future. The price-to-book ratio is listed as 0.00, which indicates that the market values the company at a fraction of its book value or that the book equity is not being recognized in the current share price, suggesting a deep discount relative to asset values. The price-to-sales ratio stands at 0.26, meaning the market capitalizes the company at roughly 26 cents for every dollar of sales, which is a very low multiple often seen in distressed or micro-cap situations. Additionally, the EV/EBITDA metric is listed as N/A, rendering this specific valuation comparison unavailable due to the negative or negligible earnings figures. The stock's price volatility is contextualized by a 52-week high of $1839.00 and a 52-week low of $1.52, showing an extreme trading range where the current share price sits significantly closer to the low end of the range relative to the high. The beta value is listed as N/A, preventing a direct assessment of the stock's price volatility relative to the broader market index based on historical sensitivity data.

Growth & Income

Revenue growth is reported at 11.9% year-over-year, indicating a positive expansion in sales, whereas earnings growth is listed as N/A due to the irregularities in the net income and EBITDA figures previously discussed. Since earnings growth data is unavailable, it is impossible to determine if earnings are growing faster or slower than revenue, though the high profit margin relative to revenue suggests potential accounting complexities rather than pure operational scaling. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all its earnings rather than distributing them to shareholders. This reinvestment strategy implies that the company prioritizes internal capital deployment for growth initiatives or debt reduction over providing income to investors. Consequently, the overall growth and income profile is characterized by positive sales momentum but a lack of current income generation or clear earnings expansion metrics.